CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase

International Immunopharmacology

Volumn 11, Issue 4, 2011, Pages 406-411

  Wang, Suna ^a   Han, Qunying ^a   Zhang, Guoyu ^a   Zhang, Ni ^a   Li, Zhu ^a   Chen, Jinghong ^a   Lv, Yi ^a   Li, Na ^a   Xing, Fanfan ^a   Tian, Ningqiang ^a   Zhu, Qianqian ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; CpG ODN; Cytotoxic T lymphocyte response; HBcAg 18 27; HIV Tat49 57; IFN

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN[18-39] HIV TRANSACTIVATOR PROTEIN[49-57] FUSION PEPTIDE; HYBRID PROTEIN; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; APOPTOSIS REGULATORY PROTEINS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 79952734782     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.12.005     Document Type: Article

References (57)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2): 97-107. (Pubitemid 38365759)
2. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45(4):1056-75. (Pubitemid 46646501)
3. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292(15):771-4.
4. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346(22):1682-3.
5. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2(3):263-83.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227-42.
7. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46(4):562-8. (Pubitemid 30305823)
8. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120(7):1828-53.
9. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123-9. (Pubitemid 40091801)
10. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12(2):351-66. (Pubitemid 29196857)
11. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984;13(4): 385-91. (Pubitemid 14102325)
12. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 2010;82(4): 539-45.
13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3): 678-86. (Pubitemid 43374518)
14. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295 (1):65-73. (Pubitemid 43042691)
15. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138(5):1747-54.
16. Ando K, Guidotti LG, Wirth S, Ishikawa T, Missale G, Moriyama T, et al. Class Irestricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994;152(7):3245-53. (Pubitemid 24098020)
17. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
18. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 2000;3(4):387-92.
19. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991;88(23): 10445-9. (Pubitemid 21915852)
20. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178(5):1541-54. (Pubitemid 23318433)
21. Milich DR, Schödel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997;71(3):2192-201. (Pubitemid 27078599)
22. Lau GK, Liang R, Lee CK, Yuen ST, Hou J, Lim WL, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis 1998;178(6):1585-91. (Pubitemid 28558127)
23. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122(3):614-24. (Pubitemid 34173812)
24. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78(11):5707-19. (Pubitemid 38661658)
25. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin- 12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997;99(12):3025-33. (Pubitemid 27278680)
26. Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999;115(3):508-14.
27. Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH. The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. J Hepatol 1999;30(3):353-8. (Pubitemid 29113220)
28. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994;91(9):3764-8. (Pubitemid 24139512)
29. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4 (1):25-36. (Pubitemid 26054933)
30. Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997;25(4):1022-7. (Pubitemid 27157151)
31. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284 (5415):825-9. (Pubitemid 29291352)
32. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191(8):1269-80. (Pubitemid 30227116)
33. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010;184(1):287-95.
34. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988;55(6):1179-88. (Pubitemid 19020070)
35. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000;97(24): 13003-8.
36. Caron NJ, Torrente Y, Camirand G, Bujold M, Chapdelaine P, Leriche K, et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther 2001;3(3):310-8. (Pubitemid 32514646)
37. Schirmbeck R, Riedl P, Zurbriggen R, Akira S, Reimann J. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9- dependent, but CD4+ T cell help-independent, priming of CD8+ T cells. J Immunol 2003;171(10):5198-207. (Pubitemid 37432804)
38. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997;159(4):1666-8. (Pubitemid 127484150)
39. Davis HL. Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 2000;247:171-83.
40. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998;95(26): 15553-8. (Pubitemid 29018737)
41. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160(2):870-6. (Pubitemid 28049329)
42. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000;18(18):1920-4. (Pubitemid 30122855)
43. Wang S, Han Q, Zhang N, Chen J, Liu Z, Zhang G, et al. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice. Immunol Lett 2010;127(2):143-9.
44. Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol 2004;10(13):1902-6. (Pubitemid 39029289)
45. Milich DR. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection. J Viral Hepat 1997;4(Suppl 2):48-59.
46. Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999;162(5):3088-95. (Pubitemid 29309340)
47. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999;30(2):531-6. (Pubitemid 29357521)
48. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997;159(3):1383-92. (Pubitemid 127484117)
49. Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999;261(2):165-72. (Pubitemid 29431769)
50. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77(1):68-76. (Pubitemid 36004947)
51. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997;71(4):3236-43. (Pubitemid 27119971)
52. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005;42(5):1028-36. (Pubitemid 43112669)
53. Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248(4953):361-4.
54. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34(5):1021-6.
55. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102(5): 968-75. (Pubitemid 28419565)
56. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33(4):963-71. (Pubitemid 32246646)
57. Kondo Y, Asabe S, Kobayashi K, Shiina M, Niitsuma H, Ueno Y, et al. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multispecificity. J Med Virol 2004;74(3):425-33. (Pubitemid 39281641)